Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nogapendekin alfa inbakicept - Altor BioScience Corporation

Drug Profile

Nogapendekin alfa inbakicept - Altor BioScience Corporation

Alternative Names: ALT 803; ANKTIVA; IL-15N72D/IL-15Ra-Fc - Altor BioScience Corporation; IL-15N72D:IL-15RαSu/Fc fusion protein complex; IL-15sa - Altor BioScience Corporation; Interleukin 15 superagonist - Altor BioScience Corporation; N-803; Nogapendekin alfa inbakicept - ImmunityBio; Nogapendekin alfa inbakicept-pmln - Altor BioScience Corporation; Superagonist Interleukin-15:Interleukin-15 receptor alphaSu/Fc Fusion complex - Altor BioScience Corporation; VesAnktiva™

Latest Information Update: 12 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Altor BioScience Corporation
  • Developer Altor BioScience Corporation; ImmunityBio
  • Class Antineoplastics; Antiretrovirals; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin-15 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Bladder cancer
  • Phase III Non-small cell lung cancer
  • Phase II Acute myeloid leukaemia; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Hereditary nonpolyposis colorectal cancer; HIV infections; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Myelodysplastic syndromes; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma; Triple negative breast cancer
  • Phase I HIV-1 infections

Most Recent Events

  • 30 May 2024 Phase-I clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (unspecified route) (NCT05618925)
  • 22 May 2024 NantKwest terminates a phase I/II QUILT3-070 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (NCT03387098)
  • 02 May 2024 ImmunityBio has patent protection for development and commercialization of N-803
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top